Latest Conference Content

Investigators conducted this subanalysis among patients aged 20 to 27 years, using data from the National Growth and Health Study to determine potential racial differences in left ventricular mass among female patients with obesity.

At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.

Javed Butler, MD, MPH, MBA, presented the analysis based on patient data from the Baylor, Scott, and White health system during the final hours of the European Society of Cardiology 2023 Congress, which concluded Monday.

There seems to be an institutional ignorance toward social determinants of health and actually making changes to improve outcomes for patients of color, said Shrilla Banerjee, MD, FRCP, consultant cardiologist, Surrey and Sussex Healthcare NHS Trust.

The EMPEROR trial showed that within 30 days of stopping empagliflozin, patients had a 70% higher risk of heart failure events, explained Milton Packer, MD, Baylor University Medical Center.

Results from the FRAIL-AF study, being presented at the European Society of Cardiology 2023 Congress, surprised the investigators.

Study investigators offered updated data from 2 key trials presented in the past year: CLEAR Outcomes in low-density lipoprotein cholesterol and OCEAN(a)-DOSE in lipoprotein (a).

Nikolaus Marx, MD, professor of medicine/cardiology and head of the Department of Internal Medicine, University Hospital Aachen, Germany, explains the new guidelines on screening for patients with type 2 diabetes and comorbid cardiovascular disease (CVD).

A symposium at the European Society of Cardiology 2023 Congress covered the spectrum from diet and exercise, to medical therapy, to evidence on newer generation stents.

When determining the success of cardiology therapies, trials should focus more on softer end points like quality of life and psychological well-being, said Donna Fitzsimons, PhD, FESC, professor of nursing at the School of Nursing and Midwifery, Queen's University Belfast.

Javed Butler, MD, MPH, MBA, said "hopefully" results from the EMPACT-MI trial should be available within the next few months.

There is a lot of drug switching that's happening, whether it's for medical or nonmedical reasons, said Steven Deitelzweig, MD, system chairman of hospital medicine at Ochsner Clinical School, professor of medicine at the University of Queensland.

With nearly a third of patients post-myocardial infarction (MI) developing heart failure, prevention is very important, said Javed Butler, MD, MPH, MBA, professor of medicine at University of Mississippi, president of the Baylor Scott & White Research Institute.

Patients who took the therapy lost weight and recorded some of the best gains in quality of life and physical improvement ever seen in this type of a study.

The interim update in heart failure reflects results from 10 clinical trials that have been published since the 2021 ESC Guidelines were released.

Lucio Gordan, MD, president and managing physician, Florida Cancer Specialists & Research Institute (FCS), discusses how FCS has learned to adapt during difficult times, including COVID-19, Hurricane Ian, and current drug shortages.

Attendees should look out for results from the STEP HFpEF program and HEART-FID trial at the European Society of Cardiology (ESC) Congress 2023, said Stephen Greene, MD, Duke University Medical Center and the Duke Clinical Research Institute.

Data from the 1999-2018 National Health and Nutrition Examination Survey were used to analyze the prevalence of social determinants of health (SDOH) among patients with self-reported heart failure (HF).

Ahead of the European Society of Cardiology (ESC) Congress 2023, John McMurray, MD, FRCP, FESC, professor of medical cardiology at the University of Glasgow, previews some themes and important topics that will be discussed at the meeting.

Neil Goldfarb, president and CEO of the Greater Philadelphia Business Coalition on Health (GPBCH), previews the upcoming GPBCH Wellness Summit taking place on September 14, 2023.

The European Society of Cardiology (ESC) 2023 Congress runs August 25-28 in Amsterdam, the Netherlands.

Data on 10 social determinants of health (SDOH) were analyzed to determine their distribution among low-income patients hospitalized for heart failure (HF) at a safety-net hospital.

Study authors investigated the effect of physical activity as a modifiable risk factor among individuals living with high-risk hypertension in this subanalysis of data from the Systolic Blood Pressure Intervention Trial (SPRINT).

Stephen Nicholls, PhD, MBBS, Monash University and Victorian Heart Hospital, explains how he works closely with patients and study sites in SURPASS-CVOT to avoid weight loss drug discontinuation and weight regain.

Sheila Garland, PhD, MSc, Memorial University in Newfoundland, Canada talks about the cognitive effects cancer can have on patients, beyond treatment side effects, and the direct impacts these can make on patients’ lives and care.

Post heart failure (HF)–related hospital discharge care was investigated among patients through evaluation of usage rates of the Heart Failure Health Storylines mobile health application.

Findings were presented by researchers from the UC Irvine Health School of Medicine at the 2023 American Society for Preventive Cardiology's Congress on CVD Prevention.

G.B. John Mancini, MD, University of British Columbia, goes into detail about the recruitment process of the VICTORION-2-PREVENT trial, which focuses on inclisiran to reduce cardiovascular risk.

Outcomes for in-hospital mortality were compared between adult patients, women vs men, among those who had both acute myocardial infarction (AMI) and heart-related mechanical complications (MC).

Stephen Nicholls, PhD, MBBS, Monash University and Victorian Heart Hospital, expands on the patient characteristics and potential impacts of COVID-19 on SURPASS-CVOT, the phase 3 cardiovascular outcomes trial for tirzepatide.